Skip to main content
logo
Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
468.41
+7.58 (1.64%)
At close: Jul 29, 2025, 4:00 PM
468.47
+0.06 (0.01%)
After-hours: Jul 29, 2025, 7:43 PM EDT

Vertex Pharmaceuticals Revenue by Segment

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Trikafta and Kaftrio
10.29B10.19B9.81B9.50B9.29B8.94B8.63B8.37B
Trikafta and Kaftrio Growth
10.80%13.95%13.59%13.46%15.77%16.36%17.33%21.24%
Kalydeco
-----475.50M499.20M525.80M
Kalydeco Growth
------14.05%-12.31%-11.23%
Orkambi
-----326.00M392.60M475.80M
Orkambi Growth
------36.17%-28.27%-18.75%
Symdeko and Semkevi
-----123.00M129.50M134.30M
Symdeko and Semkevi Growth
------31.67%-42.72%-50.13%

Revenue by Geography

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
US
6.82B6.68B6.42B6.26B6.16B6.04B5.93B5.83B
US Growth
10.75%10.67%8.37%7.47%7.35%5.98%5.21%4.81%
Europe
3.31B3.45B3.36B3.28B3.27B3.11B3.06B3.02B
Europe Growth
1.34%11.09%9.68%8.30%13.50%14.91%17.34%26.21%
Other
958.10M881.30M846.30M798.40M759.30M719.80M667.10M652.50M
Other Growth
26.18%22.44%26.86%22.36%28.11%36.87%45.31%65.90%

Operating Expense Breakdown

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Acquired In-Process Research and Development
4.57B4.63B4.56B4.60B256.80M527.10M531.90M509.20M
Acquired In-Process Research and Development Growth
1,680.14%778.09%757.06%802.47%-44.25%356.36%140.57%132.72%
Research and Development
3.82B3.63B3.46B3.39B3.21B3.16B3.03B2.87B
Research and Development Growth
19.05%14.78%13.98%18.24%19.67%24.51%25.71%28.34%
Selling, General, and Administrative
1.52B1.46B1.46B1.35B1.24B1.14B1.03B1.02B
Selling, General, and Administrative Growth
22.60%28.83%40.67%32.41%27.57%20.31%3.96%7.50%
Change in Value of Contingent Consideration
1.80M-500.00K-49.60M-48.70M-49.80M-51.60M500.00K-3.30M
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.